Navigation Links
DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
Date:6/16/2009

CUPERTINO, Calif., June 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Joseph Stauffer has joined DURECT as Chief Medical Officer and Executive Vice President, Corporate Strategy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

"Dr. Stauffer's successful leadership of clinical research and medical affairs for pain products while at Alpharma and Abbott, and first-hand experience with the regulatory approval process gained during his tenure at the U.S. Food and Drug Administration (FDA), is an ideal fit for DURECT's pipeline of acute, chronic, neuropathic and post-surgical pain products," stated James E. Brown, President and CEO of DURECT Corporation. "We're looking forward to the impact he will have on the development of POSIDUR(TM), TRANSDUR(TM)-Sufentanil, ELADUR(TM) and other programs."

Dr. Stauffer was at Alpharma Inc. from 2004 to 2009, where his latest position prior to the acquisition of Alpharma by King Pharmaceuticals was as Chief Medical Officer and Senior Vice President of Clinical Research & Medical Affairs. His responsibilities at Alpharma included oversight of all clinical pharmacology, clinical development, pharmacovigilance, medical affairs, risk management and health outcomes/pharmacoeconomics. Prior to joining Alpharma, Dr. Stauffer was employed at Abbott Laboratories from 2002 to 2004 as Global Medical Director for Pain Therapeutics. In that role, he was responsible for Phase I-III trials for Vicodin, Vicoprofen, Dilaudid, as well as novel compounds targeting neuropathic pain. Prior to Abbott, he worked at the FDA from 2000 to 2002 as a Medical Review Officer in the Analgesic Division of the Center for Drug Evaluation and Research. While there, he reviewed Investigational New Drug (IND) Applications and New Drug Applications (NDAs) for opiate, non-opiate, anti-inflammatory, and novel pain compounds.

Dr. Stauffer is a founding member of the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT). This on-going collaboration between pharma, FDA, NIH, academia and patient advocacy groups helps to develop core domains and outcomes for chronic pain clinical trials. Dr. Stauffer graduated from the Philadelphia College of Osteopathic Medicine and completed residency training in Anesthesiology at the Johns Hopkins University Hospital, where he is currently an Adjunct Assistant Professor in the Department of Anesthesiology and Critical Care Medicine. Dr. Stauffer is a veteran of the U.S. Navy, honorably discharged as a Lieutenant Commander after serving eight years as a Naval Medical Officer. He will complete his MBA in September 2009 as part of the TRIUM Global Executive MBA Program, a joint degree granted by NYU Stern School of Business, HEC School of Management (Paris) and the London School of Economics and Political Science.

"I should also note that Dr. Peter Langecker, DURECT's former Chief Medical Officer, has resigned from DURECT Corporation to pursue another opportunity," stated James E. Brown. "We want to thank Peter for his service to DURECT and wish him well on his future endeavors."

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(R), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT to Present at Merriman Curhan Fords Annual Investor Summit
2. DURECT to Present at UBS Global Life Sciences Conference
3. DURECT to Present at 2007 BIO Investor Forum
4. DURECT to Present at BIO CEO Investor Conference 2008
5. DURECT to Participate in Susquehanna Financial Healthcare Conference
6. DURECT to Participate in Cowen Annual Healthcare Conference
7. DURECT Provides Update on CHRONOGESIC(R) Research Program
8. DURECT to Participate in Morgan Stanley Global Healthcare Conference
9. DURECT Corporation Invites You to Join Its First Quarter 2008 Earnings Conference Call
10. DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference
11. DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker of coconut ... Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and celebrities the ... the big event. The invitation-only gifting suite, held this year at the W Hollywood ...
(Date:2/12/2016)... ... February 12, 2016 , ... Every winter, someone is ... winter the West Penn Burn Center, part of the Allegheny Health Network, ... to bring you the “Space Heaters Need Space” campaign. , “Space Heaters ...
(Date:2/12/2016)... Vail, Colorado (PRWEB) , ... February 12, 2016 , ... ... 164 ASC Industry Physician Leaders to Know in 2016 . The list consists of ... leaders nominated physicians to establish this list. , An Ambulatory Surgery Center, also ...
(Date:2/12/2016)... ... 2016 , ... Miami Dental Specialists is excited to bring patients the choice ... in January, Miami Dental Specialists will offer the non-metal implants as a safe, holistic ... be chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge technology to ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... about foods choices that promote eye health. These articles generally list between five ... and health advocate Sharon Kleyne endorses every one of these lists and believes ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016  Memorial Hermann Health System has teamed up ... to bring a one-of-a-kind experience to pediatric patients at ... such as 360-degree video and Google Cardboard, Howard was ... – giving the patients and their families an unexpected, ... caught on video . Memorial Hermann ...
(Date:2/12/2016)... DIEGO and SEOUL, South ... Silicon Biosys­tems Menarini and Macrogen, Inc. today announced ... assays and innovative procedures for precision medicine in ... combine Silicon Biosystems, DEPArray™ digital-sorting technology with Macrogen,s ... of tests certified under the Clinical Laboratory Improvement ...
(Date:2/12/2016)... -- OMS Supply, a large provider of oral surgery supplies ... recent launching of their new company website. The OMS ... enhance the user experience and enable practitioners to browse ... --> --> Despite the fact that ... in early 2016, they have already made an unprecedented ...
Breaking Medicine Technology: